Orthocell (ASX:OCC) Institutional Ownership : 0.03% (As of Sep. 25, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Orthocell Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Orthocell's institutional ownership is 0.03%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Orthocell's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Orthocell's Float Percentage Of Total Shares Outstanding is 0.00%.

Orthocell Institutional Ownership Historical Data

The historical data trend for Orthocell's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orthocell Institutional Ownership Chart

Orthocell Historical Data

The historical data trend for Orthocell can be seen below:

	2022-03-31	2022-04-30	2022-05-31	2022-06-30	2022-07-31	2022-08-31	2022-09-30	2022-10-31	2022-11-30	2022-12-31
Institutional Ownership	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03

Orthocell Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Orthocell Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orthocell Ltd (ASX:OCC) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

90 South Street, Building 191, Murdoch University, Murdoch, Perth, WA, AUS, 6150

Website

https://www.orthocell.com.au

Orthocell Ltd is a regenerative medicine company. The company is engaged in the development and commercialisation of cell therapies and related technologies. Its product includes CelGro is a naturally derived collagen medical device for tissue repair and Ortho-ATI is a first-in-class cell therapy for the treatment of chronic tendon injuries.